부산대학교 도서관

This document is a letter published in the journal Neurological Sciences. It discusses the use of a new therapy called efgartigimod (EFG) for the treatment of myasthenia gravis (MG), an autoimmune disorder. EFG is a humanized IgG1 Fc fragment that targets the neonatal Fc receptor (FcRn) and increases the catabolism of IgG and autoantibodies. The letter presents a case report of a patient with triple-negative MG who showed a rapid and excellent response to EFG, with improvements in clinical symptoms and quality of life. The authors emphasize the need for further research on targeted therapies for seronegative MG. [Extracted from the article]